Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 4069-4077
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.4069
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.4069
Ref. | Age (yr)/sex | Disease | Daily dose | Duration of therapy1 | Symptoms | EOS | RP | HF | CD4/CD8 | BAL | DLCO | Steroid therapy | Rechallenge /recurrence |
Le Gros et al[21] | 54/F | UC | 750 mg | 5 d | T, R | ND | I | ND | Ratio: 0.95 | Mo: 63% L: 35% E: 1.5% | 53% | No | No |
Welte et al[22] | 67/M | UC | 1 g IR | 10 d | D, DC, R | ND | I | ND | ND | ND | ND | Yes | No |
Reinoso et al[3] | 64/F | UC | 3.6 g | 2 yr | T, D, DC | ND | I | ND | ND | ND | ↓ | No | No |
Lagler et al[23] | 66/M | UC | 1.5 g | 3.5 mo | D, DC | No | I | LP | ND | Mo: 30% L: 67% | 54% | Yes | No |
Honeybourne et al[24] | 30/F | UC | 1.6 g | 7 mo | T, D, DC, CP | Yes 16% | ND | EP | ND | ND | ND | No | No |
Declerck et al[25] | 45/F | UC | 3 g | 3 mo | D | No | I | ND | ND | Mo: 45% L: 38% E: 11% | ND | No | No |
Muzzi et al[10] | 60/F | CD | 2.4 g | ND | T, D, DC | No | I | ND | CD4: 56% CD8: 31% Ratio: 1.80 | Mo: 40% L: 55% E: 3% | ND | No | Yes/No |
Bitton et al[26] | 32/F | UC | 4 g | 9 mo | T, D, DC | Yes 8.9% | ND | LP/IF | ND | ND | ND | Yes | No |
Sviri et al[27] | 49/M | CD | 3 g | 3.5 mo | T, D, DC | No | I | LP/IF | ND | L: 60% E: 10% | 80% | Yes | Yes/Yes |
Lázaro et al[28] | 60/M | UC | ND | 4 wk | T, D, DC | Yes | I | IP | ND | Mo: 80% L: 8% E: 10% | 67% | No | No |
Pascual-Lledó et al[29] | 64/F | CD | 3 g | 2 mo | D, DC, CP | No | I | NL | ND | ND | ND | No2 | No |
Sesin et al[30] | 72/F | UC | 1.6-2.4 g3 | 2 mo | T, D, CP, PC | No | ND4 | ND | ND | ND | ND | No | No |
Tanigawa et al[31] | 35/F | UC | 1.5 mg | 40 d | T, DC | Yes | I | EP | CD4: 44% CD8: 34% Ratio: 1.3 | Mo: 44% L: 49% E: 7% | ND | No | No |
Guslandi et al[32] | 29/F | UC | 3 g | 2 d | D, CP | No | ND | ND | ND | ND | ND | No | Yes/Yes |
Facchini et al[33] | 15/M | UC | 2.8 g | 4 mo | D, DC | No | A | ND | ND | ND | ND | Yes | No |
Zamir et al[34] | 23/F | UC | ND | 6 wk | F, DC | Yes | ND | ND | ND | ND | ND | Yes | No |
Saltzman et al[35] | 53/F | UC | ND | 4 mo | T, DC, R | Yes 27% | A | EP | ND | E: 79% | ND | Yes | No |
Haralambou et al[36] | 18/F | UC | 1.6 g P.O. + 4 g (enema) | 2 mo | T, D, DC, CP | Yes 88% | I | BO | ND | ND | ND | Yes | No |
Sossai et al[6] | 70/F | UC | 2.4 g | 3 mo | D, DC | No | I | IP | Ratio: 0.39 | Mo: 40% L: 60% | ND | No | N/A5 |
Pérez et al[37] | 50/M | UC | 4 g | 2 mo | T, D, DC | ND | ND | EP | ND | ND | ND | Yes | No |
Foster et al[5] | 44/M | CD | 2.4-4.8 g | 15 mo | T, D, DC | No | A | IP/IF | ND | N: 73% | ND | Yes | No |
30/F | UC | 4.8 g | 2 yr | T, D, DC, CP | No | A | IP/IF | ND | N: 43% | ND | No | No | |
29/F | UC | 3.6 g | 8 mo | T, D, DC | No | A | IP | ND | ND | 19% | Yes | No | |
Hakoda et al[38] | 30/M | UC | 2.25 g | 4 wk | T, DC | Yes | ND | EP | ND | ND | ND | Yes | No |
Actis et al[39] | 57/M | UC | ND | 2 yr | T, D, DC, CP | No | A | ND | ND | ND | ↓ | Yes | No |
Kohli et al[40] | 10/F | UC | 3.2 g | 2 wk | T, D, DC | Yes 12% | I | IP | ND | ND | ND | Yes | Yes/Yes |
Katsenos et al[41] | 18/M | UC | ND | 1 yr | T, PC | Yes | I | ND | ND | Mo: 15% L: 20% E: 60% | ND | Yes | No |
Price et al[11] | 28/F | UC | 1.2 g | 4-5 yr | T, PC | Yes | B | ND | ND | N: 95% | ND | Yes | Yes/No6 |
Iannone et al[42] | 32/F | UC | ND | 4 mo | T, DC | No | I | ND | ND | ND | 74% | Yes | No |
Cilloniz et al[43] | 14/M | CD | 3 g | 8 mo | CP | No | I | IP | ND | Mo: 68% L: 27% | 93% | Yes | No |
Park et al[44] | 35/M | CD | 4 g | 3 mo | T, DC | Yes 32% | I | EP | CD4: 54% CD8: 41% Ratio: 1.3 | L: 31% E: 41% | ND | No | No |
Shimizu et al[45] | 50/F | UC | ND | 4 wk | T, DC | ND | ND | ND | ND | L: 58% E: 20% | ND | No | No |
Sposato et al[46] | 42/M | UC | 3.2 g | 8 d | T, CP | Yes 14% | I | ND | ND | Mo: 13% E: 47% N: 34% | ND | Yes7 | No |
Lamsiah et al[47] | 57/F | UC | ND (enemas) | 3 mo | T, D, DC | Yes | I | ND | ND | ND | ND | Yes | Yes/Yes8 |
Kevans et al[48] | 17/M | UC | 4 g | 3 mo | D, DC, CP | Yes 23% | A | ND | ND | ND | ND | Yes | No |
Abraham et al[49] | 65/M | UC | 4.8 g | 2 wk | T, D, DC9 | No | I | LP/IF | ND | ND | ND | Yes | No |
Kim et al[50] | 30/F | UC | 1 g IR | 19 d | PC | Yes 24% | I | EP | ND | Mo: 73% N: 19% | ND | Yes | No |
Michy et al[12] | 72/M | UC | ND | 4 mo | D | Yes | ND | EP | ND | L: 23% N: 28% E: 14% | ND | Yes | Yes/No10 |
Current case | 32/M | UC | 1.5-3 g3 | 14 mo | T, D, DC, CP | Yes 62% | I | EP | CD4: 29% CD8: 56% Ratio: 0.51 | E: 72% | 67% | Yes | No |
Ref. | Age (yr)/sex | Disease | Daily dose | Duration of therapy | Symptoms | Cardiac disease | Pharmacologic treatment | Rechallenge /recurrence |
Vayre et al[51] | 53/M | CD | 500 mg | 8 yr | T, CP | AP, PE | Prednisolone | No |
Ishikawa et al[16] | 17/M | UC | 1.5 g | 2 wk | T, CP | AP, PE | Prednisolone | Yes/Yes |
Doganay et al[52] | 21/M | UC | 2 g | 10 d | T, D | AM | Budesonide | No |
García-Morán et al[17] | 39/M | UC | 4 g P.O. + 2 g (enemas) | 2 d | T, CP | AM, AMI | Methylprednisolone | No |
Martín et al[53] | 22/M | UC | 3 g | ND | CP | AM | Corticosteroids | No |
Cappell et al[15] | 32/M | UC | ND | 10 yr | T, CP, D | Chronic pericarditis, PT | Prednisone | No |
Bernal-Sprekelsen et al[54] | 54/M | UC | 1.5 g | 3 wk | T, CP | AP, PE | ASA | Yes/Yes1 |
Freeman et al[55] | 26/M | UC | 1.6 g | 3 wk | T, CP | AM | Hydrocortisone | Yes/No2 |
Sierra Ausín et al[56] | 47/M | UC | 3 g P.O. + 1 g (enemas) | 3 wk | T, CP | AP | NSAIDs | No |
Park et al[57] | 26/M | UC | 2.4 g | 1 mo | T, CP | AM, PE | ASA, prednisolone | Yes/Yes |
Calafat et al[13] | 37/M | UC | 1 g IR | 1 mo | CP | AP, PE | ASA | No |
37/F | UC | 3g | 2 wk | CP | AP, PE | Analgesics | No | |
Sonu et al[58] | 20/F | UC | Sulfasalazine 2 g + mesalazine (enemas)3 | 3 wk | CP | AM, PT | Ibuprofen and colchicine | Yes/Yes4 |
Current case | 32/M | UC | 1.5-3 g5 | 14 mo | T, CP, D | AP, PE | Prednisone | No |
- Citation: Ferrusquía J, Pérez-Martínez I, Gómez de la Torre R, Fernández-Almira ML, de Francisco R, Rodrigo L, Riestra S. Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity. World J Gastroenterol 2015; 21(13): 4069-4077
- URL: https://www.wjgnet.com/1007-9327/full/v21/i13/4069.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i13.4069